Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
08 Gennaio 2008 - 2:00PM
PR Newswire (US)
BOTHELL, Wash., Jan. 8 /PRNewswire-FirstCall/ -- Nastech
Pharmaceutical Company Inc. (NASDAQ:NSTK) announced the completion
of enrollment for its Phase 2 clinical trial of PYY3-36 Nasal Spray
to treat obesity. The Company enrolled 551 obese patients at
multiple clinical sites in the United States for a six-month,
randomized, placebo-controlled dose ranging study. The study is
designed to evaluate three different doses of PYY3-36 Nasal Spray
compared to placebo and sibutramine (Meridia(R)), a commercially
available oral weight loss drug, with the primary endpoint being
weight loss. "We are pleased with the rapid enrollment of 551
patients into the Phase 2 study to evaluate PYY3-36 nasal spray as
a novel treatment for obesity. The fact that we exceeded our
enrollment target of 510 patients is an indication of the unmet
need for an effective obesity therapeutic," stated Gordon Brandt,
M.D., President of Nastech. "The dramatic rise in obesity globally
requires safe and effective treatment options for the hundreds of
millions of people whose lives are impacted by this condition. If
successful, PYY Nasal Spray would offer a patient-friendly product
to promote weight loss." About PYY Peptide YY is a naturally
occurring hormone that is believed to function as a physiologic
inhibitor of food intake. PYY is released into the blood stream
from specialized endocrine cells (L-cells) in the gut after a meal
and is believed to trigger the feeling of satiety, or fullness.
Because PYY is a peptide, initial studies focused on PYY delivery
by injection. Utilizing its proprietary drug delivery technology,
Nastech developed the nasal spray formulation of PYY as a unique,
non-invasive treatment option for obesity. About Nastech Nastech is
a biopharmaceutical company developing innovative products based on
proprietary molecular biology-based drug delivery technologies.
Nastech is creating technologies that enable the delivery of
peptide and protein therapeutics without the requirement of an
injection, which is currently the most common form of
administration for this class of drugs. Nastech has also
established a wholly-owned subsidiary, MDRNA, Inc., to focus on
developing RNA-based technologies and therapeutics. MDRNA is
harnessing the power of RNA interference, a cellular mechanism that
can turn off the production of a specific protein through use of
small interfering RNAs (siRNAs), to develop a new class of
therapeutics by identifying key protein targets, designing the
siRNAs that will turn off the production of the targeted proteins,
and creating a formulation for the delivery of the therapeutics.
Nastech and its collaboration partners are developing products for
multiple therapeutic areas including osteoporosis, obesity,
diabetes, autism, respiratory diseases and inflammatory conditions.
For additional information about Nastech please visit
http://www.nastech.com/. Nastech Forward Looking Statements
Statements made in this press release may be forward-looking
statements within the meaning of Federal Securities laws that are
subject to certain risks and uncertainties and involve factors that
may cause actual results to differ materially from those projected
or suggested. Factors that could cause actual results to differ
materially from those in forward-looking statements include, but
are not limited to: (i) the ability of Nastech or a subsidiary to
obtain additional funding; (ii) the ability of Nastech or a
subsidiary to attract and/or maintain manufacturing, research,
development and commercialization partners; (iii) the ability of
Nastech, a subsidiary and/or a partner to successfully complete
product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of
Nastech, a subsidiary and/or a partner to obtain required
governmental approvals; and (v) the ability of Nastech, a
subsidiary and/or a partner to develop and commercialize products
that can compete favorably with those of competitors. Additional
factors that could cause actual results to differ materially from
those projected or suggested in any forward-looking statements are
contained in Nastech's most recent periodic reports on Form 10-K
and Form 10-Q that are filed with the Securities and Exchange
Commission. Nastech assumes no obligation to update and supplement
forward-looking statements because of subsequent events. Contacts:
Nastech Ed Bell Director, Investor Relations (425) 908-3639 Russo
Partners, LLC David Schull (Media) (212) 845-4271 DATASOURCE:
Nastech Pharmaceutical Company Inc. CONTACT: Ed Bell, Director,
Investor Relations of Nastech, +1-425-908-3639, , or Media, David
Schull of Russo Partners, LLC, +1-212-845-4271, for Nastech Web
site: http://www.nastech.com/
Copyright
Grafico Azioni Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Nastech Pharmaceutical Company (MM) (NASDAQ): 0 articoli recenti
Più Nastech Pharmaceutical Company (MM) Articoli Notizie